ArticleLifetime data analysis2026
Estimating heterogeneous treatment effects with survival outcomes via a deep survival learner.
Article in Lifetime data analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Estimating heterogeneous treatment effects in survival settings is complicated by right censoring as well as the time-varying nature of the estimand. While the conditional average treatment effect (CATE) provides a natural target, most existing approaches focus on a single prespecified time point and do not account for temporal trajectory, leading to instability in estimation. We propose a deep survival learner (DSL) for estimating heterogeneous treatment effects with right-censored outcomes. The method is based on a doubly robust pseudo-outcome whose conditional expectation identifies time-specific CATEs under standard assumptions. This construction remains unbiased if either the outcome model or the treatment assignment model is correctly specified, when properly accounting for censoring. To estimate CATEs over a clinically relevant time spectrum, DSL employs a multi-output deep neural network with shared representations, enabling joint estimation of treatment effect trajectories. From a theoretical perspective, we derive error bounds for both pointwise and joint estimation over time. We show that joint estimation can leverage temporal structure to control estimation error without incurring much additional approximation cost under smoothness conditions, leading to improved stability relative to separate estimation. Cross-fitting is incorporated to reduce overfitting and mitigate bias arising from flexible nuisance estimation. Simulation studies demonstrate favorable finite-sample performance, particularly under nuisance model misspecification. Applied to the Boston Lung Cancer Study, DSL reveals heterogeneity in the effects of perioperative chemotherapy across patient characteristics and over time.
Indexed as
Identifiers
42878981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.